NASDAQ:BIIB

Biogen Price Target, Predictions & Analyst Ratings

$355.74
-16.16 (-4.35 %)
(As of 06/24/2021 10:34 AM ET)
Add
Compare
Today's Range
$339.70
$363.52
50-Day Range
$259.00
$414.71
52-Week Range
$223.25
$468.55
Volume108,894 shs
Average Volume1.58 million shs
Market Capitalization$53.56 billion
P/E Ratio18.66
Dividend YieldN/A
Beta0.44

Biogen (NASDAQ:BIIB) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
32 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $387.93, predicting that the stock has a possible upside of 9.05%. The high price target for BIIB is $500.00 and the low price target for BIIB is $244.00. There are currently 14 hold ratings and 18 buy ratings for the stock, resulting in a consensus rating of "Buy."
TypeToday30 Days Ago90 Days Ago180 Days Ago
BIIB Consensus Rating: BuyHoldHoldHold
BIIB Consensus Rating Score: 2.562.272.222.24
BIIB Analyst Ratings: 0 Sell Rating(s)
14 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
14 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
15 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
15 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
BIIB Consensus Price Target: $387.93$305.39$304.47$306.13
BIIB Price Target Upside: 9.05% upside5.58% upside4.46% upside2.79% upside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen (NASDAQ:BIIB) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021Piper Sandler
UpgradeNeutral ➝ Overweight$384.00 ➝ $450.00Low
6/15/2021Bank of America
Reiterated RatingBuy$415.00Low
6/14/2021The Goldman Sachs Group
Boost Price TargetAverage ➝ Neutral$246.00 ➝ $436.00Low
6/11/2021Sanford C. Bernstein
UpgradeMarket Perform ➝ Outperform$500.00Medium
6/10/2021UBS Group
UpgradeNeutral ➝ Buy$463.00Low
6/10/2021SVB Leerink
Boost Price TargetOutperform$380.00 ➝ $475.00Medium
6/8/2021William Blair
UpgradeMarket Perform ➝ OutperformHigh
6/8/2021Royal Bank of Canada
Boost Price TargetSector Perform$259.00 ➝ $400.00High
6/8/2021Jefferies Financial Group
Boost Price TargetBuy$450.00 ➝ $500.00Medium
6/8/2021Morgan Stanley
Boost Price TargetOverweight$343.00 ➝ $455.00Medium
6/8/2021Barclays
Boost Price TargetEqual Weight$265.00 ➝ $395.00Medium
6/8/2021HC Wainwright
Boost Price TargetBuy$305.00 ➝ $452.00Medium
6/8/2021Citigroup
UpgradeSell ➝ NeutralMedium
6/8/2021Atlantic Securities
UpgradeUnderweight ➝ Neutral$415.00Low
6/8/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell
UpgradeSell ➝ Neutral$200.00 ➝ $440.00Low
6/7/2021Robert W. Baird
UpgradeUnderperform ➝ Neutral$216.00 ➝ $382.00Medium
6/7/2021Raymond James
UpgradeUnderperform ➝ Market PerformMedium
6/7/2021Cowen
UpgradeMarket Perform ➝ Outperform$225.00 ➝ $450.00High
5/18/2021Oppenheimer
Boost Price TargetOutperform$300.00 ➝ $325.00Low
4/12/2021Wedbush
Boost Price TargetNeutral$236.00 ➝ $245.00Medium
2/17/2021Cantor Fitzgerald
Lower Price TargetNeutral$278.00 ➝ $268.00Low
2/5/2021DZ Bank
DowngradeBuy ➝ Hold$264.00Low
2/4/2021Credit Suisse Group
Lower Price TargetOutperform$388.00 ➝ $350.00Medium
1/29/2021Stifel Nicolaus
UpgradeHold ➝ Buy$258.00 ➝ $358.00High
11/10/2020Truist
DowngradeBuy$310.00 ➝ $443.00Low
11/9/2020Mizuho
Lower Price TargetNeutral$282.00 ➝ $244.00Medium
11/5/2020Canaccord Genuity
Boost Price TargetBuy$350.00 ➝ $393.00High
11/5/2020BMO Capital Markets
UpgradeMarket Perform$280.00 ➝ $343.00High
11/4/2020Wells Fargo & Company
UpgradeEqual Weight ➝ Overweight$437.00 ➝ $390.00High
9/13/2020JPMorgan Chase & Co.
Reiterated RatingHoldHigh
7/8/2020SunTrust Banks
Reiterated RatingBuy$330.00Low
7/8/2020Guggenheim
Reiterated RatingBuy$390.00Low
3/31/2020Wolfe Research
Initiated CoverageMarket Perform$331.00Low
2/7/2020Nomura Securities
Boost Price TargetBuy$320.00 ➝ $392.00Low
11/1/2019Standpoint Research
DowngradeBuy ➝ HoldLow
7/26/2019Piper Jaffray Companies
Reiterated RatingHoldN/A
5/7/2019Argus
Reiterated RatingHoldHigh
3/21/2019BTIG Research
DowngradeBuy ➝ NeutralHigh
(Data available from 6/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.